Circulating biomarkers in patients with heart failure and preserved ejection fraction. Curr Heart Fail Rep. 2013;10:350 8. 71. Karayannis G, Triposkiadis F, Skoularigis J, et al. The emerging role of Ga- lectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. Curr Heart Fail Rep. 2013;10:441 9. 72. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart fail- ure. J Am Coll Cardiol HF. 2014;2:260 8. 73. Bayes-Genis A, de AM, Vila J, et al. Head-to-head comparison of 2 myo- cardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63:158 66. 74. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. J Am Coll Cardiol HF. 2014;2:65 72. 75. Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5:183 90. 76. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of mul- tiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012;125:233 40. 77. Ahmad T, Fiuzat M, Pencina MJ, et al. Charting a roadmap for heart failure biomarker studies. J Am Coll Cardiol HF. 2014;2:477 88. 78. Miller WL, Hartman KA, Grill DE, et al. Serial measurements of midre- gion proANP and copeptin in ambulatory patients with heart failure: in- cremental prognostic value of novel biomarkers in heart failure. Heart. 2012;98:389 94. 79. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomark- ers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483 95. 80. 